In MuSK MG, the pathogenic antibodies are usually directed to the first Ig-like domain in MuSK and reduce MuSK phosphorylation by impairing binding between Lrp4 and MuSK (Huijbers et al., 2013; Koneczny et al., 2013). The gene discussed is LRP4; the disease is myasthenia gravis.